Brenner tumor

Summary

Brenner tumor (MONDO:0024235) is a cancer and 7 clinical trials. Top therapeutic interventions include carboplatin, belinostat, and erlotinib. A subtype of reproductive system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Brenner tumor
Mondo ID	MONDO:0024235
MeSH	D001948
NCIT	C39954
UMLS	C0006160
MedGen	2345
Is cancer (heuristic)	yes

Also known as: Brenner tumor

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › reproductive system neoplasm › Brenner tumor

Related subtypes (8): benign reproductive system neoplasm, reproductive system cancer, sex cord-stromal tumor, gonadal tissue neoplasm, pituitary tumor, female reproductive system neoplasm, prostate neoplasm, male reproductive system neoplasm

Subtypes (3): ovarian Brenner tumor, testicular Brenner tumor, extraovarian Brenner tumor of the vagina

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00059787	PHASE2	COMPLETED	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
NCT00466960	PHASE2	COMPLETED	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
NCT00993616	PHASE2	COMPLETED	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
NCT02122185	PHASE2	COMPLETED	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00002913	PHASE1	COMPLETED	Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
NCT00079430	PHASE1	COMPLETED	Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00085358	PHASE1	COMPLETED	Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	4
BELINOSTAT	4	1
ERLOTINIB	4	1
METFORMIN	4	1